Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07121192 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

A Phase 2 study of Influenza, Human, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 2
Development phase
776
Enrollment target
20
Study locations

NCT07121192 is a Phase 2 study of Influenza, Human that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 776 participants, below the 16,180-participant average among 18 other Influenza, Human trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07121192, a Phase 2 study of Influenza, Human, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
776 participants
Enrollment target
20
Study locations

Study Summary

"The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults."

Conditions Studied

Influenza, Human

Interventions

  • COMBINATION_PRODUCT Comparator 1
  • COMBINATION_PRODUCT Comparator 2
  • BIOLOGICAL Flu mRNA (Formulation A)
  • BIOLOGICAL Flu mRNA (Formulation B)
  • COMBINATION_PRODUCT Comparator 3

Study Locations (20)

California

  • GSK Investigational Site - Fair Oaks
  • GSK Investigational Site - San Diego
  • GSK Investigational Site - San Diego
  • GSK Investigational Site - Walnut Creek

Florida

  • GSK Investigational Site - Hialeah
  • GSK Investigational Site - Jupiter
  • GSK Investigational Site - Miami

Texas

  • GSK Investigational Site - Austin
  • GSK Investigational Site - DeSoto
  • GSK Investigational Site - Fort Worth

Alabama

  • GSK Investigational Site - Anniston

Georgia

  • GSK Investigational Site - Atlanta

Indiana

  • GSK Investigational Site - Valparaiso

Kansas

  • GSK Investigational Site - Lenexa

Massachusetts

  • GSK Investigational Site - Springfield

Trial Details

FieldValue
Enrollment Target 776 participants
Start Date 2025-08-25
Est. Completion 2026-05-15
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07121192

The ClinicalTrials.gov registry entry for NCT07121192 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 776 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 16,180-participant average among 18 other Influenza, Human trials with a reported enrollment target (95% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Influenza, Human appearing as the primary indexed condition, and to 5 interventions - of which Comparator 1 is the first listed.

NCT07121192 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT07121192 about?

NCT07121192 is a clinical study titled "A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older". "The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults."

What is the current status of trial NCT07121192?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 776 participants. The study started on 2025-08-25. Estimated completion is 2026-05-15.

What conditions does trial NCT07121192 study?

This clinical trial studies the following conditions: Influenza, Human.

What interventions are being tested in trial NCT07121192?

The interventions under investigation include: Comparator 1 (COMBINATION_PRODUCT), Comparator 2 (COMBINATION_PRODUCT), Flu mRNA (Formulation A) (BIOLOGICAL), Flu mRNA (Formulation B) (BIOLOGICAL), Comparator 3 (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT07121192?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07121192 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Influenza, Human

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Influenza, Human

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.